Florfenikel

Main information

  • Trade name:
  • Florfenikel
  • Pharmaceutical form:
  • Solution for injection
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Florfenikel
    Portugal
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • florfenicol
  • Therapeutic area:
  • Cattle, Pigs

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0379/001
  • Authorization date:
  • 26-10-2011
  • EU code:
  • UK/V/0379/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Issued:February2012

AN:00791/2010

Page1of4

SUMMARYOFPRODUCTCHARACTERISTICS

1.NAMEOFTHEVETERINARYMEDICINALPRODUCT

NL,CZ,FR,DE,IE,IT,PL,BE,BG,CY,GR,HU,LU,PT,RO,SK:FLORFENIKEL300

mg/mlsolutionforinjectionforpigs

ES,DK:KELAFLOR300mg/mlsolutionforinjectionforpigs

2.QUALITATIVEANDQUANTITATIVECOMPOSITION

Eachmlcontains

Activesubstance:

Florfenicol300mg

Forafulllistofexcipients,seesection6.1.

3.PHARMACEUTICALFORM

SolutionforInjection.

Clear,lightyellowtoyellowsolution.

4.CLINICALPARTICULARS

4.1TargetSpecies

Pigs.

4.2Indicationsforuse,specifyingthetargetspecies

Diseasescausedbyflorfenicolsusceptiblebacteria.

Pigs:Treatmentofacuteoutbreaksofswinerespiratorydiseasecausedbystrainsof

ActinobacilluspleuropneumoniaeandPasteurellamultocidasusceptibletoflorfenicol.

4.3Contraindications

Donotuseinboarsintendedforbreedingpurposes.

Donotuseinpigletsoflessthan2kg.

Donotadministertoanimalswithknownhypersensitivitytoflorfenicolortoanyofthe

excipients.

Donotadministerintravenously.

4.4Specialwarningsforeachtargetspecies

None.

4.5Specialprecautionsforuse

(i)Specialprecautionsforuseinanimals

Theproductshouldbeusedinconjunctionwithsusceptibilitytestingandtakeinto

accountofficialandlocalantimicrobialpolicies.

Issued:February2012

AN:00791/2010

Page2of4

Thestoppermustbecleanedbeforeremovingeachdose.Useadry,sterilesyringeand

needle.

(ii)Specialprecautionstobetakenbythepersonadministeringthemedicinalproductto

animals

Careshouldbetakentoavoidaccidentalself-injection.Incaseofself-injection,seek

medicaladviceimmediatelyandshowthepackageleafletorthelabeltothephysician.

Avoiddirectcontactwithskin,mouthandeyes.Ifeyeexposureoccurs,flusheyes

immediatelywithcleanwater.Ifskinexposureoccurs,washtheaffectedareawithclean

water.Ifaccidentalingestionoccurs,rinsethemouthwithplentyofwaterandseek

medicaladviceimmediately.

Washhandsafteruse.

Peoplewithknownhypersensitivitytoflorfenicolshouldavoidcontactwiththeproduct.

(iii)Otherprecautions

None

4.6Adversereactions(frequencyandseriousness)

Commonlyobservedadverseeffectsaretransientdiarrhoeaand/orperi-analandrectal

erythema/oedemawhichmayaffect50%oftheanimals.Theseeffectscanbeobserved

foroneweek.

Transientswellinglastingupto5daysmaybeobservedatthesiteofinjection.

Inflammatorylesionsattheinjectionsitemaybeseenupto28days.

Underfieldconditions,approximately30%oftreatedpigsmaypresentwithpyrexia

(40oC)associatedwitheithermoderatedepressionormoderatedyspnoeaaweekor

moreafteradministrationoftheseconddose.

4.7Useduringpregnancy,lactationorlay

Studiesinlaboratoryspecieshavenotproducedanyevidenceofteratogenicor

foetotoxiceffects.Safetyduringpregnancyandlactationhasnotbeeninvestigatedin

thetargetspecies.Useonlyaccordinglytothebenefit/riskassessmentbythe

responsibleveterinarian.

4.8Interactionwithothermedicinalproductsandotherformsofinteraction

Nodataavailable.

4.9Amountstobeadministeredandadministrationroute

Toensureacorrectdosagebodyweightshouldbedeterminedasaccuratelyaspossible

toavoidunderdosing.Thevialcannotbebroachedmorethan25times.

IMinjectionof15mg/kgBW(1ml/20kg)intotheneckmuscletwice48hourapart.

Thevolumeadministeredperinjectionsiteshouldnotexceed3ml.Subsequent

injectionsmustbegivenatdifferentsites.

Issued:February2012

AN:00791/2010

Page3of4

Itisrecommendedtotreatanimalsintheearlystagesofdiseaseandtoevaluatethe

responsetotreatmentwithin48hoursafterthesecondinjection.Ifclinicalsignsof

respiratorydiseasepersist48hoursafterthelastinjection,treatmentshouldbechanged

usinganotherformulationoranotherantibioticandcontinueduntilclinicalsignshave

resolved.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Inswineafteradministrationof3timestherecommendeddoseormoreareductionin

feeding,hydrationandweightgainhasbeenobserved.Afteradministrationof5times

therecommendeddoseormorevomitinghasalsobeennoted.

4.11WithdrawalPeriod(s)

Meatandoffal:18days

5.PHARMACOLOGICALorIMMUNOLOGICALPROPERTIES

Pharmacoterapeuticgroup:Antibacterialsforsystemicuse,amphenicols,Florfenicol

ATCvetcode:QJ01BA90

5.1Pharmacodynamicproperties

FlorfenicolisasyntheticbroadspectrumantibioticeffectiveagainstmostGram-positive

andGram-negativebacteriaisolatedfromdomesticanimals.Florfenicolactsby

inhibitingproteinsynthesisattheribosomallevelandisbacteriostatic.

However,bactericidalactivityhasbeendemonstratedinvitroagainstmostcommon

bacterialpathogensinvolvedinrespiratorydisease:

- Actinobacilluspleuropneumoniaisolatedinpigs.

- Pasteurellamultocidaisolatedincattleandpigs .

Acquiredresistancetoflorfenicolismediatedbyeffluxpumpresistanceassociatedwith

aflogene.Crossresistancewithchloramphenicolcanoccur.

5.2Pharmacokineticproperties

Afterintramuscularadministrationoftherecommendeddoseof15mg/kg,maximum

serumconcentrationof2.48µg/mlisreachedafter2.0hoursandtheconcentrations

depletewithaterminalhalf-lifeof14.9hours.

Serumconcentrationsdropbelow1µg/ml,theMIC90forthetargetporcinepathogens,

12-24hoursfollowingIMadministrationFlorfenicolconcentrationsachievedinlung

tissuereflectplasmaconcentration,withalung:plasmaconcentrationratioof

approximately1.Afteradministrationtopigsbytheintramuscularroute,florfenicolis

rapidlyexcreted,primarilyinurine.Theflorfenicolisextensivelymetabolised.

6PHARMACEUTICALPARTICULARS

6.1Listofexcipients

N-Methylpyrrolidone

Glycerolformal

Issued:February2012

AN:00791/2010

Page4of4

6.2Incompatibilities

Intheabsenceofcompatibilitystudies,thisveterinarymedicinalproductmustnotbe

mixedwithotherveterinarymedicinalproducts.

6.3Shelf-life

Shelf-lifeoftheveterinarymedicinalproductaspackagedforsale:2years

Followingwithdrawalofthefirstdose,usetheproductwithin28days.

6.4Specialprecautionsforstorage

Storethebottleintheoutercartoninordertoprotectfromdirectsunlight.

6.5Natureandcompositionofimmediatepackaging

Vialsizes:100and250ml

-ColourlessTypeIIglassvialsclosedwithbromobutylrubberclosuresandan

aluminiumcap.

-Polypropylenevialsclosedwithbromobutylrubberclosuresandanaluminiumcap.

Vialsareindividuallypackedincartonbox.

Six,tenortwelveofthesearegroupedasclinicalpack.

Notallpacksizesmaybemarketed.

6.6Specialprecautionsforthedisposalofunusedveterinarymedicinalproducts

orwastematerials

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuch

veterinarymedicinalproductsshouldbedisposedofinaccordancewithlocal

requirements.

7.MARKETINGAUTHORISATIONHOLDER

KELAN.V.

St.Lenaartseweg48

2320Hoogstraten

Belgium

8.MARKETINGAUTHORISATIONNUMBER

Vm06126/4001

9.DATEOFTHEFIRSTAUTHORISATION

27February2012

7-12-2018

Magnesium citrate malate as a source of magnesium added for nutritional purposes to food supplements

Magnesium citrate malate as a source of magnesium added for nutritional purposes to food supplements

Published on: Thu, 06 Dec 2018 The present scientific opinion deals with the assessment of the bioavailability of magnesium, from the proposed nutrient source, magnesium citrate malate (MgCM), when added for nutritional purposes to food supplements. MgCM is a mixed salt consisting of magnesium cations and citrate and malate anions, and with a magnesium content of 12–15%. MgCM is proposed to be used in food supplements that are intended to provide up to 300–540 mg/day magnesium. The data provided demonst...

Europe - EFSA - European Food Safety Authority Publications

15-11-2018

Safety evaluation of the food enzyme acetolactate decarboxylase from a genetically modified Bacillus licheniformis (strain NZYM‐JB)

Safety evaluation of the food enzyme acetolactate decarboxylase from a genetically modified Bacillus licheniformis (strain NZYM‐JB)

Published on: Wed, 14 Nov 2018 The food enzyme acetolactate decarboxylase (α‐acetolactate decarboxylase; EC 4.1.1.5) is produced with a genetically modified Bacillus licheniformis strain NZYM‐JB by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. This acetolactate decarboxylase is intended to be used in distilled alcohol production and brewing processes. Residual amounts of total organi...

Europe - EFSA - European Food Safety Authority Publications

14-11-2018

“Vita-X Revitalizing Capsules” for men may pose serious health risks

“Vita-X Revitalizing Capsules” for men may pose serious health risks

Health Canada is advising Canadians that two versions of “Vita-X Revitalizing Capsules” by Lanlay Healthmetic Inc., promoted for “long lasting vital energy for men,” may pose serious health risks. One version contains seven capsules and has “NPN 80053009,” a Natural Product Number (NPN) indicating Health Canada authorization, on the label. The second version contains one capsule, has no NPN on the label and is not authorized by Health Canada.

Health Canada

30-10-2018

Sciegen Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Irbesartan Tablets, USP  75 Mg, 150 Mg, and 300 Mg Due to The Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in The Active Pharmaceutical Ingredient (API)

Sciegen Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Irbesartan Tablets, USP 75 Mg, 150 Mg, and 300 Mg Due to The Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in The Active Pharmaceutical Ingredient (API)

ScieGen Pharmaceuticals, Inc. is voluntarily recalling listed lots, within expiry, of Irbesartan Tablets, USP 75 mg, 150 mg, and 300 mg dosage forms to the consumer level. These products are being recalled due to the presence of an impurity, N-nitrosodiethylamine (NDEA) contained in the API Irbesartan, USP manufactured by Aurobindo Pharma Limited. This impurity, which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, has been classified as a...

FDA - U.S. Food and Drug Administration

30-10-2018

Pest categorisation of Aleurocanthus spp.

Pest categorisation of Aleurocanthus spp.

Published on: Mon, 29 Oct 2018 00:00:00 +0100 The Panel on Plant Health performed a pest categorisation of Aleurocanthus spp., a well‐defined insect genus of the whitefly family Aleyrodidae (Arthropoda: Hemiptera). Difficulties within the taxonomy of the genus give doubt about the ability to accurately identify some members to species level. Nevertheless, the genus is thought to currently include about ninety species mainly reported from tropical and subtropical areas. The genus is listed in Council Dir...

Europe - EFSA - European Food Safety Authority Publications

18-10-2018

Stewart’s Shops Issues Allergy Alert on Undeclared Milk in Cranberry Apple Refresher

Stewart’s Shops Issues Allergy Alert on Undeclared Milk in Cranberry Apple Refresher

Saratoga Springs, NY - Stewart’s Shops Corp. is recalling units of Stewart’s Shops brand Cranberry Apple Refresher 16 fluid oz. because the product may contain undeclared milk. People who have an allergy to milk run the risk of serious or life-threatening allergic reaction if they consume this product. Approximately 2,300 units of affected product were distributed in upstate New York and Southern Vermont.

FDA - U.S. Food and Drug Administration

12-9-2018

FDA takes new steps to address epidemic of youth e-cigarette use, including a historic action against more than 1,300 retailers and 5 major manufacturers for their roles perpetuating youth access

FDA takes new steps to address epidemic of youth e-cigarette use, including a historic action against more than 1,300 retailers and 5 major manufacturers for their roles perpetuating youth access

FDA takes new steps to address epidemic of youth e-cigarette use, including a historic action against more than 1,300 retailers and 5 major manufacturers for their roles perpetuating youth access

FDA - U.S. Food and Drug Administration

19-7-2018

Openfoodtox: over 300 substances added to EFSA chemical hazards database

Openfoodtox: over 300 substances added to EFSA chemical hazards database

Openfoodtox: over 300 substances added to EFSA chemical hazards database

Europe - EFSA - European Food Safety Authority Press Releases & News Stories

17-5-2018

JAGUAR 30000 capsules

JAGUAR 30000 capsules

Safety advisory

Therapeutic Goods Administration - Australia

27-4-2018

EpiPen 300 mcg adrenaline auto-injector

EpiPen 300 mcg adrenaline auto-injector

Medicine shortages

Therapeutic Goods Administration - Australia

13-6-2017

Annual report 2016 - Clinical trials of medicines

Annual report 2016 - Clinical trials of medicines

LLast year, the Danish Medicines Agency received 286 clinical trial applications. This is a small decline compared to 2015. However, the number of clinical trial applications has remained stable at around 300 applications per year since 2013.

Danish Medicines Agency

6-4-2017

More batches of EpiPen® are withdrawn

More batches of EpiPen® are withdrawn

MEDA has decided to withdraw four more batches of EpiPen®. The withdrawal concerns two batches of EpiPen® 300 micrograms/dose and two batches of EpiPen® Jr 150 micrograms/dose. The latter is used for acute hypersensitivity reactions in children. The reason for the withdrawal is that there is a risk that the auto-injector does not work.

Danish Medicines Agency

17-3-2017

Withdrawal of a batch of EpiPen® 300 micrograms

Withdrawal of a batch of EpiPen® 300 micrograms

MEDA recalls a batch of the adrenaline product EpiPen® 300 micrograms/dose, which is used for sudden allergic reactions. There is a risk that the auto-injector does not work. The withdrawal concerns product number 578818 with batch number: 5FA665B and expiry date 03/2017.

Danish Medicines Agency

21-2-2017

Takeda Pharma A/S recalls batch of Pamol® in packs of 300 film-coated tablets

Takeda Pharma A/S recalls batch of Pamol® in packs of 300 film-coated tablets

Takeda Pharma A/S recalls a batch of Pamol® in packs of 300 film-coated tablets after the discovery of Ibumetin 600 mg containing ibuprofen in some packs. Both types of medicine are used for the treatment of mild pain, but they work in different ways and may cause different adverse reactions.

Danish Medicines Agency

21-11-2018

Osurnia (Elanco GmbH)

Osurnia (Elanco GmbH)

Osurnia (Active substance: terbinafine / florfenicol / betamethasone acetate) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)7842 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/003753/T/0010

Europe -DG Health and Food Safety

27-6-2018

Yondelis (Pharma Mar S.A.)

Yondelis (Pharma Mar S.A.)

Yondelis (Active substance: Trabectedin) - PSUSA - Modification - Commission Decision (2018)4096 of Wed, 27 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/3001/201709

Europe -DG Health and Food Safety

29-5-2018

Osurnia (Elanco Europe Ltd)

Osurnia (Elanco Europe Ltd)

Osurnia (Active substance: terbinafine / florfenicol / betamethasone acetate) - Centralised - Yearly update - Commission Decision (2018)3406 of Tue, 29 May 2018

Europe -DG Health and Food Safety

16-5-2018

Busulfan Fresenius Kabi (Fresenius Kabi Deutschland GmbH)

Busulfan Fresenius Kabi (Fresenius Kabi Deutschland GmbH)

Busulfan Fresenius Kabi (Active substance: busulfan) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3005 of Wed, 16 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2806/T/8

Europe -DG Health and Food Safety

15-5-2018

Lonquex (UAB Sicor Biotech)

Lonquex (UAB Sicor Biotech)

Lonquex (Active substance: lipegfilgrastim) - Centralised - Renewal - Commission Decision (2018)3009 of Tue, 15 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2556/R/39

Europe -DG Health and Food Safety

15-5-2018

Izba (Novartis Europharm Limited)

Izba (Novartis Europharm Limited)

Izba (Active substance: travoprost) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3002 of Tue, 15 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2738/T/10

Europe -DG Health and Food Safety

15-5-2018

KEYTRUDA (Merck Sharp and Dohme B.V.)

KEYTRUDA (Merck Sharp and Dohme B.V.)

KEYTRUDA (Active substance: pembrolizumab) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3003 of Tue, 15 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/3820/T/45

Europe -DG Health and Food Safety

15-5-2018

LIFMIOR (Pfizer Limited)

LIFMIOR (Pfizer Limited)

LIFMIOR (Active substance: etanercept) - Centralised - Yearly update - Commission Decision (2018)3004 of Tue, 15 May 2018

Europe -DG Health and Food Safety

15-5-2018

Travatan (Novartis Europharm Limited)

Travatan (Novartis Europharm Limited)

Travatan (Active substance: Travoprost) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3001 of Tue, 15 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/390/T/59

Europe -DG Health and Food Safety

15-5-2018

Imatinib Teva B.V. (Teva B.V.)

Imatinib Teva B.V. (Teva B.V.)

Imatinib Teva B.V. (Active substance: imatinib) - Centralised - Withdrawal - Commission Decision (2018)3008 of Tue, 15 May 2018

Europe -DG Health and Food Safety

15-5-2018

Instanyl (Takeda Pharma A/S)

Instanyl (Takeda Pharma A/S)

Instanyl (Active substance: Fentanyl ) - PSUSA - Modification - Commission Decision (2018)3006 of Tue, 15 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/959/PSUSA/1369/201704

Europe -DG Health and Food Safety

15-5-2018

PecFent (Kyowa Kirin Services Ltd)

PecFent (Kyowa Kirin Services Ltd)

PecFent (Active substance: Fentanyl ) - PSUSA - Modification - Commission Decision (2018)3007 of Tue, 15 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1164/PSUSA/1369-201704

Europe -DG Health and Food Safety